Drug Profile
Aspirin/hydrochlorothiazide/enalapril/atorvastatin - Alborz-Darou Pharmaceutical
Alternative Names: PolyIran 1; PolyPill 4-1Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Alborz Darou
- Developer Alborz Darou; Golestan University of Medical Sciences; Tehran University of Medical Sciences; University of Birmingham
- Class Amides; Antihyperlipidaemics; Antihypertensives; Antiplatelets; Benzothiadiazines; Cardiovascular therapies; Dipeptides; Esters; Fatty acids; Fluorobenzenes; Heptanoic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Pyrrolidines; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 11 Oct 2021 No development reported - Phase-III for Cardiovascular disorders (Prevention) in Iran (PO) (NCT01271985)
- 11 Oct 2018 Chemical structure information added
- 05 Sep 2018 Phase III development is ongoing in Iran (Alborz-Darou Pharmaceutical website, September 2018)